Predictive factors for epidermal growth factor receptor inhibitors - The bull's-eye hits the arrow

被引：73

作者：

Dancey, JE ^{[1
]}

机构：

[1] NCI, Canc Therapy Evaluat Program, Invest Drug Branch, Rockville, MD 20852 USA

来源：

CANCER CELL | 2004年 / 5卷 / 05期

关键词：

D O I：

10.1016/S1535-6108(04)00122-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Studies have shown that epidermal growth factor receptor (EGFR) signaling is important to normal development and neoplastic transformation, and that EGFR inhibition reduces cancer cell proliferation. The promising response rates of the EGFR inhibitor gefitinib in patients with chemotherapy-refractory non-small cell lung cancer (NSCLC) led to its approval for clinical use. However, there was little understanding of why gefitinib was effective in only some NSCLC patients. Two recent studies have identified somatic mutations in EGFR that confer its sensitivity to gefitinib in vitro and correlate strongly with patients' clinical response to the inhibitor.

引用

页码：411 / 415

页数：5

共 31 条

[1] Cigarette smoking and histologic type of lung cancer in men [J].

Barbone, F ;

Bovenzi, M ;

Cavallieri, F ;

Stanta, G .

CHEST, 1997, 112 (06) :1474-1479

[2] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[3]

Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO

[4]

2-T

[5] United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets [J].

Cohen, MH ;

Williams, GA ;

Sridhara, R ;

Chen, G ;

McGuinn, WD ;

Morse, D ;

Abraham, S ;

Rahman, A ;

Liang, CY ;

Lostritto, R ;

Baird, A ;

Pazdur, R .

CLINICAL CANCER RESEARCH, 2004, 10 (04) :1212-1218

[6] EPIDERMAL GROWTH-FACTOR [J].

COHEN, S .

BIOSCIENCE REPORTS, 1986, 6 (12) :1017-1028

[7] CLOSE SIMILARITY OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND V-ERB-B ONCOGENE PROTEIN SEQUENCES [J].

DOWNWARD, J ;

YARDEN, Y ;

MAYES, E ;

SCRACE, G ;

TOTTY, N ;

STOCKWELL, P ;

ULLRICH, A ;

SCHLESSINGER, J ;

WATERFIELD, MD .

NATURE, 1984, 307 (5951) :521-527

[8]

EKSTRAND AJ, 1991, CANCER RES, V51, P2164

[9] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[10] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1 [J].

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Scagliotti, G ;

Rosell, R ;

Miller, V ;

Natale, RB ;

Schiller, JH ;

von Pawel, J ;

Pluzanska, A ;

Gatzemeier, M ;

Grous, J ;

Ochs, JS ;

Averbuch, SD ;

Wolf, MK ;

Rennie, P ;

Fandi, A ;

Johnson, DH .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :777-784

← 1 2 3 4 →